<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font22 { font-size : 22; } .font30 { font-size : 30; } .font31 { font-size : 31; }</style>
 <body>
  <p>
   <span class="font31">infections </span>
   <span class="font30">viral </span>
   <span class="font22">infection </span>
   <span class="font20">(n=) </span>
   <span class="font19">allo-HCT </span>
   <span class="font18">(.–.) </span>
   <span class="font18">incidence </span>
   <span class="font18">patients </span>
   <span class="font17">EBV </span>
   <span class="font17">cell </span>
   <span class="font17">;():–. </span>
   <span class="font17">risk </span>
   <span class="font16">{border-style </span>
   <span class="font15">(n=), </span>
   <span class="font15">CMV </span>
   <span class="font15">acute </span>
   <span class="font15">hematopoietic </span>
   <span class="font15">px;} </span>
   <span class="font15">treatment </span>
   <span class="font15">#ffffff;} </span>
   <span class="font15">antiviral </span>
   <span class="font15">children </span>
   <span class="font14">stem </span>
   <span class="font14">HCT </span>
   <span class="font14">auto-HCT </span>
   <span class="font14">(.%) </span>
   <span class="font14">significant </span>
   <span class="font14">specific </span>
   <span class="font14">transplantation </span>
   <span class="font14">used </span>
   <span class="font14">Infections </span>
   <span class="font14">infection. </span>
   <span class="font14">therapy </span>
   <span class="font14">virus </span>
   <span class="font14">virus; </span>
   <span class="font13">EBV-DNA-emia </span>
   <span class="font13">Marrow </span>
   <span class="font13">leukemia </span>
   <span class="font13">observed </span>
   <span class="font13">pediatric </span>
   <span class="font13">respiratory </span>
   <span class="font13">study </span>
   <span class="font13">ADV </span>
   <span class="font13">BKV </span>
   <span class="font13">factors </span>
   <span class="font13">CMV, </span>
   <span class="font13">European </span>
   <span class="font13">Infect </span>
   <span class="font13">n=; </span>
   <span class="font13">patients. </span>
   <span class="font13">primary </span>
   <span class="font13">unrelated </span>
   <span class="font12">Transplant. </span>
   <span class="font12">Viral </span>
   <span class="font12">development </span>
   <span class="font12">diagnosis </span>
   <span class="font12">donor; </span>
   <span class="font12">drugs </span>
   <span class="font12">human </span>
   <span class="font12">infection, </span>
   <span class="font12">infectious </span>
   <span class="font12">matched </span>
   <span class="font12">patients, </span>
   <span class="font12">reactivation </span>
   <span class="font12">rituximab </span>
   <span class="font12">(HR=.; </span>
   <span class="font12">Ganciclovir </span>
   <span class="font12">MSD </span>
   <span class="font12">Risk </span>
   <span class="font12">allogeneic </span>
   <span class="font12">cases </span>
   <span class="font12">days </span>
   <span class="font12">episodes </span>
   <span class="font12">frequent </span>
   <span class="font12">influenza </span>
   <span class="font12">mortality </span>
   <span class="font12">period </span>
   <span class="font12">pre-emptive </span>
   <span class="font12">px; </span>
   <span class="font12">{font-family </span>
   <span class="font12">&amp;lt;. </span>
   <span class="font12">Department </span>
   <span class="font12">EBV, </span>
   <span class="font12">HSV, </span>
   <span class="font12">NoV </span>
   <span class="font12">Pediatric </span>
   <span class="font12">Table </span>
   <span class="font12">University </span>
   <span class="font12">VZV, </span>
   <span class="font12">analysis </span>
   <span class="font12">complications </span>
   <span class="font12">cumulative </span>
   <span class="font12">disease </span>
   <span class="font12">donor </span>
   <span class="font12">font-size </span>
   <span class="font12">median </span>
   <span class="font12">occurred </span>
   <span class="font12">patient </span>
   <span class="font12">prevent </span>
   <span class="font12">reported </span>
   <span class="font12">time </span>
   <span class="font12">treated </span>
   <span class="font11">Blood </span>
   <span class="font11">Bone </span>
   <span class="font11">Cidofovir </span>
   <span class="font11">Conference </span>
   <span class="font11">Dis. </span>
   <span class="font11">HHV-, </span>
   <span class="font11">Infection </span>
   <span class="font11">Infectious </span>
   <span class="font11">RhV, </span>
   <span class="font11">allo-HCT, </span>
   <span class="font11">bold </span>
   <span class="font11">cause </span>
   <span class="font11">conditioning; </span>
   <span class="font11">data </span>
   <span class="font11">death </span>
   <span class="font11">did </span>
   <span class="font11">double; </span>
   <span class="font11">guidelines </span>
   <span class="font11">infection: </span>
   <span class="font11">lymphoblastic </span>
   <span class="font11">nationwide </span>
   <span class="font11">recommended </span>
   <span class="font11">total </span>
   <span class="font11">use </span>
   <span class="font11">viruses </span>
   <span class="font11">.StyczynskiJ, </span>
   <span class="font11">Analysis </span>
   <span class="font11">CMV-IgG </span>
   <span class="font11">Collegium </span>
   <span class="font11">Epstein–Barr </span>
   <span class="font11">FLUAV, </span>
   <span class="font11">HPIV, </span>
   <span class="font11">Medical </span>
   <span class="font11">NoV, </span>
   <span class="font11">RSV, </span>
   <span class="font11">RV, </span>
   <span class="font11">a/cGVHD, </span>
   <span class="font11">bone </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">cases, </span>
   <span class="font11">evidence </span>
   <span class="font11">factor </span>
   <span class="font11">given </span>
   <span class="font11">graft </span>
   <span class="font11">hMPV, </span>
   <span class="font11">host </span>
   <span class="font11">infections. </span>
   <span class="font11">latent </span>
   <span class="font11">lymphoma; </span>
   <span class="font11">multicenter </span>
   <span class="font11">post-transplant </span>
   <span class="font11">prophylaxis </span>
   <span class="font11">recipients </span>
   <span class="font11">shown </span>
   <span class="font11">solid; </span>
   <span class="font11">survival </span>
   <span class="font11">symptomatic </span>
   <span class="font11">undergoing </span>
   <span class="font11">using </span>
   <span class="font11">versus </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font11">(Table </span>
   <span class="font11">(for </span>
   <span class="font11">BKV, </span>
   <span class="font11">Cell </span>
   <span class="font11">Copernicus </span>
   <span class="font11">Czyzewski </span>
   <span class="font11">Drug </span>
   <span class="font11">FLUAV </span>
   <span class="font11">Factor </span>
   <span class="font11">Factors </span>
   <span class="font11">Foscarnet </span>
   <span class="font11">GVHD </span>
   <span class="font11">HCT, </span>
   <span class="font11">Hematology </span>
   <span class="font11">Hodgkin </span>
   <span class="font11">IVIG </span>
   <span class="font11">MMUD </span>
   <span class="font11">MUD </span>
   <span class="font11">Nicolaus </span>
   <span class="font11">Non-Hodgkin </span>
   <span class="font11">Number </span>
   <span class="font11">Oncology </span>
   <span class="font11">PCR </span>
   <span class="font11">PVB </span>
   <span class="font11">Survival </span>
   <span class="font11">Transpl </span>
   <span class="font11">adolescents </span>
   <span class="font11">available </span>
   <span class="font11">case </span>
   <span class="font11">caused </span>
   <span class="font11">cidofovir </span>
   <span class="font11">courier; </span>
   <span class="font11">currently </span>
   <span class="font11">cytomegalovirus </span>
   <span class="font11">day </span>
   <span class="font11">deaths </span>
   <span class="font11">defined </span>
   <span class="font11">diagnosed </span>
   <span class="font11">disease; </span>
   <span class="font11">doi:./bmt.. </span>
   <span class="font11">doi:./tid...issue- </span>
   <span class="font11">em; </span>
   <span class="font11">epidemiology, </span>
   <span class="font11">following </span>
   <span class="font11">herpesvirus </span>
   <span class="font11">higher </span>
   <span class="font11">immunosuppressive </span>
   <span class="font11">impact </span>
   <span class="font11">infections, </span>
   <span class="font11">leukemia; </span>
   <span class="font11">lymphoproliferative </span>
   <span class="font11">management </span>
   <span class="font11">multiple </span>
   <span class="font11">performed </span>
   <span class="font11">pharmacotherapy </span>
   <span class="font11">preceded </span>
   <span class="font11">pt;} </span>
   <span class="font11">rate </span>
   <span class="font11">recipient </span>
   <span class="font11">recipients. </span>
   <span class="font11">setting. </span>
   <span class="font11">sibling </span>
   <span class="font11">statistically </span>
   <span class="font11">syncytial </span>
   <span class="font11">therapies </span>
   <span class="font11">therapy. </span>
   <span class="font11">transplant </span>
   <span class="font11">transplantation. </span>
   <span class="font11">varicella-zoster </span>
   <span class="font11">work </span>
   <span class="font11">yes </span>
  </p>
 </body>
</html>
